skip to Main Content

Aiding Immune Responses Through CXCR4 Inhibition in Patients With Pancreatic Cancer

Aiding Immune Responses Through CXCR4 Inhibition in Patients With Pancreatic Cancer
For roughly 10 years, researchers at Cold Spring Harbor Laboratory  have been studying the tumor microenvironment in pancreatic cancer. More specifically, they are evaluating how it can prevent a T-cell attack of the cancer cells, said Douglas Fearon, MD.

In a phase I study, Fearon and his colleagues discovered that inhibiting the chemokine receptor type 4 (CXCR4) for one week can activate immune reactions in cancer cells and tumor biopsies. The study also led to the discovery that CXCR4 protects all of the cancer cells and CXCL-12 coats several adenocarcinomas. Read more . . .


Back To Top